Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion | Synapse
March 3, 2026Open Access
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion
Key Points
ABM-1310 demonstrates favorable safety and encouraging intracranial activity for patients with BRAF-mutated tumors.
The study shows that intracranial activity was particularly notable in patients with prior BRAF inhibitor exposure.
Assessment involved evaluating safety and efficacy, focusing on advanced solid tumors driven by BRAF mutations.
These findings support the continued exploration of ABM-1310 in treating CNS tumors and BRAF-inhibitor-experienced patient populations.
Abstract
ABM-1310 showed a favorable safety profile and encouraging intracranial activity. These findings support continued evaluation for CNS tumors and in cancer patients with prior BRAF inhibitor exposure.